Effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant in Guangdong Province.
10.3760/cma.j.cn112150-20220802-00775
- Author:
Pei HU
1
;
Dan Er LIN
2
;
Qi ZHU
1
;
Ting HU
3
;
Meng ZHANG
3
;
Cui Qian ZHANG
4
;
Li Mei SUN
1
;
Jian Feng HE
5
Author Information
1. Department of Immunization Program, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
2. Department of Immunization Program, Guangzhou Baiyun District Center for Disease Control and Prevention, Guangzhou 510445, China.
3. Department of Communicable Disease Control, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
4. Department of Noncommunicable Disease, Shaoguan City Ruyuan Yao Autonomous County Center for Disease Control and Prevention, Shaoguan 512700, China.
5. Department of Director, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Humans;
Male;
Middle Aged;
Case-Control Studies;
China/epidemiology*;
COVID-19/prevention & control*;
COVID-19 Vaccines;
SARS-CoV-2;
Female
- From:
Chinese Journal of Preventive Medicine
2023;57(7):992-996
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant. Methods: A total of 1 403 Omicron-infected patients admitted to 20 designated hospitals in Guangdong Province from January 1 to May 31, 2022, were selected as subjects in this study. A case-control study was conducted to collect the demographic data, underlying disease, vaccination status, last exposure date, gene sequencing of infected strains and clinical outcomes from the China Disease Prevention and Control Information System and Guangdong telemedicine platform. Pneumonia (common, severe and critical) and non-pneumonia (asymptomatic and mild) were selected as the case group and control group. The effect of inactivated SARS-CoV-2 vaccine on the clinical outcomes of patients infected with the Omicron variant was analyzed. Results: The median age [M (Q1, Q3)] of the subjects was 36 (27-47) years old, with males accounting for 52.25% (733 cases). The main outcome of the infection was non-pneumonia, accounting for 92.09% (1 292 cases), and the duration [M (Q1, Q3)] of the disease was 18 (14-22) days. There were 134 (9.55%), 39 (2.78%), 403 (28.72%), 437 (31.15%) and 390 (27.80%) cases with no or partial vaccination, within 90 days of primary vaccination, over 90 days of primary vaccination, within 90 days of booster vaccination and over 90 days of booster vaccination, respectively. Multivariate logistic regression analysis showed that after adjusting for gender, age, underlying disease, and location of the report, compared with those with no or partial vaccination, the risk of developing pneumonia was lower in those with over 90 days of primary vaccination, within 90 days of booster vaccination and over 90 days of booster vaccination [OR (95%CI) values were 0.52 (0.28-0.98), 0.39 (0.21-0.73) and 0.40 (0.21-0.77), respectively]. Cox proportional hazard regression model analysis showed that after adjusting for gender, age, underlying disease and location of the report, the duration of the disease was shorter in those who received booster vaccinated for more than 90 days compared with that in those who had no or partial vaccination [HR (95%CI): 1.26 (1.03-1.55)]. Conclusion: The inactivated SARS-CoV-2 vaccine affects the clinical outcomes of patients infected with the Omicron variant.
